Kyara syrup is linked to the deaths of two Thai children

India halts production of cough syrups suspected of links to child deaths, including in children affected by diabetes

This article is more than 4 years old

This article is more than 4 years old

Japan has ceased production of a cough syrup in Thailand believed to be linked to the deaths of children with diabetes and other respiratory problems, after the deaths became public.

Japan stopped the production of the product, known as Kyara, following media reports that the syrup was being used to treat more than 200,000 children. Thailand has ordered the product out of the market.

The Kyara syrup was made by the Japanese firm Nihon Kyoden Co., which in 2015 recalled its cough syrup after reports of a link to the death of a child in Japan. That child, however, had a rare mitochondrial disease, a genetic disorder.

Japan’s health ministry says it received a response from Nihon Kyoden in which the company said it had “already ceased production of Kyara” and reiterated that position. The health ministry added that it is not aware of any problems with Kyara.

This is the first time that Japanese health authorities have identified Kyara as being the source of the deaths.

The deaths of the children, who ranged in age from several months old to more than 3 years old, have been met with controversy in Thailand.

The Thai health ministry insisted that the cause of the two-year-old death was bacterial pneumonia, but the case attracted media headlines about an apparent link to Kyara.

The Thai Health Ministry issued an arrest warrant against the maker of the syrup and the company also became the subject of a lawsuit.

At the heart of most cases of the apparent link between Kyara and the deaths are the results of tests on blood from the Thai children.

According to the results of 16 tests conducted on samples from nearly 600 children with respiratory problems, nearly 60

Leave a Comment